Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-LNP (Wassermann Medic)
- Development stage
- Unknown
- Lead developer
- Wassermann Medic
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intralesional
01
Overview
mRNA-LNP (Wassermann Medic) is an investigational mRNA-based therapeutic formulated in lipid nanoparticles (LNPs) for the treatment of non-melanoma skin cancer (NMSC). Developed by Wassermann Medic in collaboration with Almirall, the therapy utilizes messenger RNA to encode specific therapeutic proteins that are expressed locally within the tumor microenvironment. These proteins are intended to exert an antineoplastic effect, potentially by inducing apoptosis in cancerous cells or modulating the local immune response to recognize and eliminate the tumor. The lipid nanoparticle delivery system is critical for protecting the mRNA from enzymatic degradation and facilitating its efficient entry into target skin cells. The program is currently in Phase 1 clinical development, representing a strategic expansion of Almirall's dermatology-focused pipeline into advanced genetic and RNA-based therapies.
- Other names
- mRNA-lipid nanoparticle (Wassermann Medic)Wassermann Medic mRNA-LNPWasserman Medic mRNA-LNP
Beyond the preview
Go deeper on mRNA-LNP (Wassermann Medic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-LNP (Wassermann Medic).